Skip to main content
. 2021 Nov 25;11:774445. doi: 10.3389/fonc.2021.774445

Figure 1.

Figure 1

(A), Kaplan–Meier survival curves of progression-free survival; (B), overall survival; (C), PFS of Cam+XELOX+Bev vs Cam+XELOX+Rego (p > 0.05); and (D), PFS in patients with or without liver metastasis (p > 0.05); Cam, camrelizumab; Bev, bevacizumab; Rego, regorafenib; XELOX, capecitabine and oxaliplatin.